Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01094444
Other study ID # 09.15
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2010
Est. completion date November 2014

Study information

Verified date November 2020
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to explore the benefit of topical vitamin K3 lotion for the reactivation/rephosphorylation of EGF-receptor in the skin and the possible reduction in cutaneous side effects of EGFr-inhibition. Primary aim: The possible reduction of cutaneous side effects: folliculitis, dryness and redness of the skin. Secondary aim: To explore any possible side effects of topical vitamin K3 lotion. Methods: 36 patients with metastatic colorectal cancer or metastatic head and neck cancer allocated to treatment with chemotherapy and biweekly cetuximab. Two equally sized areas of at least 10x10 cm on the back or chest of the patient is marked. Patients receive in a double blinded procedure placebo lotion on one side and vitamin K3 lotion on the other side. The treatment may last for a maximum of two months and the patients are followed biweekly with photos, VAS-scores, questionnaires and CTCAE estimations. The patient will be able to take weekly photos at home during the weeks they are not seen at the outpatient clinic. During the treatment all other skin products or antibiotics is allowed and will be carefully registered by the health care professionals in the outpatient clinic. The patient may enter the trial in two different ways: 18 patients start treatment with study lotions at the time they start treatment with cetuximab. The other 18 patients start treatment with study lotions when folliculitis appears. Patients are asked for 1.5 mm skin biopsies of both study areas of the skin before start of treatment and after 4 weeks of treatment with placebo lotion and vitamin K3 lotion. These biopsies will be investigated for EGFr, phosphorylated EGFr and other central downstream mechanisms. The biopsy part of the study is optional for the patient.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Planned or ongoing treatment with cetuximab - Age at least 18 years - Informed written consent according to local and national legislation Exclusion Criteria: - Known disease that can influence either treatment, evaluation and the outcome of the current disease and treatment, including chronic dermatology - Known hypersensitivity to menadion - Concomitant treatment with Vitamin K or Vitamin K-antagonists - Known psychological, family, sociological or geographic conditions which potentially can influence planned study treatment or follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vitamin K3
Lotion containing 1.5 mM Vitamin K3

Locations

Country Name City State
Denmark Odense University Hospital Odense C

Sponsors (1)

Lead Sponsor Collaborator
Per Pfeiffer

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. 2017 Jul;25(7):2179-2185. doi: 10.1007/s00520-017-3623-x. Epub 2017 Feb 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Potential reduction in skin toxicity by vitamin K3 lotion Reduction in numbers of papulo-pustular eruptions in the treatment fields. Changes in follicular eruptions, dryness/redness of skin estimated by CTCAE 4.0. Patients own experience of efficacy estimated by questionaire and VAS scale. 3 months
Secondary Potential toxicity of vitamin K3 lotion No systemic or skin toxicity is expected. Therefore all experienced skin changes will be estimated by CTCAE 4.0. Furthermore, broad bloodtest screenings will be done bi-weekly. 3 months
See also
  Status Clinical Trial Phase
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT05345093 - Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, and Folliculitis N/A
Completed NCT06052241 - Artificial Intelligence-based Prescription of Personalized Scalp Cosmetics N/A
Completed NCT00289588 - An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers N/A
Completed NCT05793164 - Characterization and Risk Factors of Folliculitis After Hair Transplantation
Completed NCT01126268 - Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection Phase 4
Suspended NCT01244256 - Efficacy and Comparative of the Association Beclomethasone Clotrimzaol + Gentamicin in Patients With Acne Contaminated Phase 2/Phase 3